Ernexa Therapeutics Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ernexa Therapeutics Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $582.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $68.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | $5.80M | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $19.81M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $23.34M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $21.27M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $22.31M | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $24.52M | Mar 9, 2017 |
| FY2015 | Dec 31, 2014 | $26.05M | Mar 15, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $5.80M | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $19.81M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $23.34M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $21.27M | Mar 22, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $23.75M | Mar 31, 2014 |
| FY2012 | Dec 31, 2012 | $5.93M | Mar 29, 2013 |
| FY2012 | Sep 30, 2012 | $6.05M | Mar 29, 2013 |
| FY2012 | Jun 30, 2012 | $6.02M | Mar 29, 2013 |
| FY2012 | Mar 31, 2012 | $6.07M | Mar 29, 2013 |
| FY2012 | Dec 31, 2011 | $6.10M | Mar 29, 2013 |
| FY2012 | Sep 30, 2011 | $5.87M | Mar 29, 2013 |
| FY2012 | Jun 30, 2011 | $5.89M | Mar 29, 2013 |
| FY2012 | Mar 31, 2011 | $6.00M | Mar 29, 2013 |
| FY2011 | Dec 31, 2010 | $25.31M | Mar 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $486.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($168.0K) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 14, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.08M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($44.54M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($21.67M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($24.58M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($122.55M) | Mar 20, 2023 |
| FY2021 | Sep 30, 2021 | ($85.99M) | Jul 1, 2022 |
| FY2021 | Jun 30, 2021 | ($28.61M) | Jul 1, 2022 |
| FY2021 | Mar 31, 2021 | ($18.52M) | Jul 1, 2022 |
| FY2021 | Dec 31, 2020 | ($7.29M) | Jul 1, 2022 |
| FY2020 | Dec 31, 2019 | ($2.05M) | Mar 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.32M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($15.67M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($21.14M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($33.22M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($113.73M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($7.25M) | Jul 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.76M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $203.0K | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($1.40M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($2.28M) | Mar 9, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.0K | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $26.0K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $72.0K | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $139.0K | Mar 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $8.09M | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $13.18M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $14.46M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $15.59M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $16.46M | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $18.06M | Mar 9, 2017 |
| FY2015 | Dec 31, 2014 | $18.37M | Mar 15, 2016 |
| FY2014 | Dec 31, 2013 | $16.22M | Mar 27, 2015 |
| FY2013 | Dec 31, 2012 | $18.25M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $20.45M | Mar 29, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.02M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($15.84M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($20.41M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($20.98M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($23.49M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($8.10M) | Jul 1, 2022 |
| FY2020 | Dec 31, 2019 | $2.74M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.37M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $549.0K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $23.0K | Mar 9, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.0K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $369.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $19.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $297.0K | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $154.0K | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $39.0K | Jul 1, 2022 |
| FY2019 | Dec 31, 2019 | $128.0K | Mar 19, 2020 |
| FY2019 | Dec 31, 2018 | $648.0K | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $728.0K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $427.0K | Mar 9, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.83M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.27M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $49.13M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $22.28M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $31.53M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $12.91M | Jul 1, 2022 |
| FY2020 | Dec 31, 2019 | $14.13M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $14.86M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $16.57M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $16.70M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.43M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.57M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $46.90M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $10.17M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $6.02M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $5.25M | Jul 1, 2022 |
| FY2020 | Dec 31, 2019 | $9.03M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $7.95M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $11.03M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $12.63M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.40M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.70M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.23M | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $12.11M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $25.50M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $7.66M | Mar 20, 2023 |
| FY2021 | Dec 31, 2019 | $9.74M | Jul 1, 2022 |
| FY2020 | Dec 31, 2018 | $6.92M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $5.54M | Mar 19, 2020 |
| FY2018 | Dec 31, 2016 | $4.07M | Mar 22, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.04M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.04M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.04M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $2.04M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $2.04M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $2.04M | Jul 1, 2022 |
| FY2020 | Dec 31, 2019 | $696.0K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $667.0K | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.00M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $937.0K | Mar 9, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($245.64M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($231.54M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($186.98M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($165.30M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($140.70M) | Mar 20, 2023 |
| FY2021 | Sep 30, 2021 | ($132.74M) | Jul 1, 2022 |
| FY2021 | Jun 30, 2021 | ($46.76M) | Jul 1, 2022 |
| FY2021 | Mar 31, 2021 | ($36.66M) | Jul 1, 2022 |
| FY2021 | Dec 31, 2020 | ($18.14M) | Jul 1, 2022 |
| FY2020 | Dec 31, 2019 | ($131.46M) | Mar 11, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.73M | Mar 12, 2025 |
| FY2024 | Dec 31, 2023 | $7.58M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $11.45M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $16.99M | Mar 20, 2023 |
| FY2020 | Dec 31, 2020 | $777.0K | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $3.21M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $2.54M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $3.38M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $5.69M | Mar 9, 2018 |
| FY2017 | Dec 31, 2015 | $3.22M | Mar 9, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $3.75M | Mar 22, 2019 |
| FY2017 | Dec 31, 2017 | $5.12M | Mar 9, 2018 |
| FY2016 | Dec 31, 2016 | $8.11M | Mar 9, 2017 |
| FY2015 | Dec 31, 2015 | $7.44M | Mar 15, 2016 |
| FY2014 | Dec 31, 2014 | $5.32M | Mar 27, 2015 |
| FY2013 | Dec 31, 2013 | $1.59M | Mar 31, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (48) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (8) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (56) | Mar 20, 2023 |
| FY2021 | Sep 30, 2021 | (1) | Jul 1, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Jul 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Jul 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (48) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (8) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (56) | Mar 20, 2023 |
| FY2021 | Sep 30, 2021 | (1) | Jul 1, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Jul 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Jul 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.85M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 3.43M | Mar 13, 2026 |
| FY2024 | Oct 29, 2024 | 51.39M | Mar 12, 2025 |
| FY2024 | Dec 31, 2023 | 5.41M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 5.13M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 2.60M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Jul 1, 2022 |
| FY2020 | Dec 31, 2019 | 2.90M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 2.88M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 2.52M | Mar 22, 2019 |